|
Market Closed -
Nasdaq
00:30:00 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.5399 USD | +5.72% |
|
+2.22% | -81.19% |
| 10-14 | Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director | CI |
| 10-07 | Sensorion: Louis J. Arcudi III appointed chief financial officer |  |
Company Valuation: Tempest Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 8.93 | - |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -36.85% | - |
| Enterprise Value (EV) | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 8.93 | 8.93 |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -36.85% | 0% |
| P/E | - | -0.37x | -2.3x | -0.56x | -0.45x | -0.19x | -0.6x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | 0.1x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | -40.17 | -24.83 | -19.5 | -6.33 | -2.85 | -0.9 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | -26.99 | -34.64 | -28.78 | - | -26.31 | - | - |
| EBIT | -26.99 | -34.64 | -29.16 | -42.03 | -26.58 | - | - |
| Net income | - | -35.71 | -29.49 | -41.84 | -26.26 | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 68.6400 | 14.9500 | 57.2000 | 10.8485 | 2.8700 | 0.5399 | 0.5399 |
| Nbr of stocks (in thousands) | 532 | 809 | 1,481 | 3,357 | 4,927 | 16,540 | - |
| Announcement Date | 29/03/22 | 22/03/23 | 19/03/24 | 27/03/25 | 30/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18x | - | - | - | 8.93M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 64.14B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 55.53B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.03B | |
| 35.05x | 3.37x | 14.55x | -.--% | 45.99B | |
| 48.28x | 5.55x | 30.42x | -.--% | 42.45B | |
| -19.33x | 186.93x | -20.57x | -.--% | 40.45B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.25B | |
| 36.51x | 6.64x | 22.27x | -.--% | 34.47B | |
| 26.96x | 5.67x | 14.71x | -.--% | 24.23B | |
| Average | 24.17x | 26.33x | 15.57x | 0.34% | 39.26B | |
| Weighted average by Cap. | 26.73x | 24.89x | 15.80x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TPST Stock
- Valuation Tempest Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
